Comparison of sleep disorders in diabetic and non-diabetic subjects with Metabolic dysfunction–associated steatotic liver disease (MASLD)
This cross-sectional study of 230 Iranian adults found that while diabetes is associated with a higher prevalence of obstructive sleep apnea and MASLD with increased rates of insomnia and excessive daytime somnolence, the presence of diabetes does not further exacerbate sleep disorder severity in patients with MASLD.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Sleep is more than just a period of rest; it is a vital biological process that helps regulate how the body handles energy, manages blood sugar, and controls inflammation. When this process is disrupted, the consequences can ripple through the entire system, contributing to conditions like obesity and type 2 diabetes. At the same time, a common liver condition known as metabolic dysfunction–associated steatotic liver disease, or MASLD, is rising in prevalence worldwide. This condition involves an excess of fat in the liver, often linked to metabolic issues such as high blood pressure and diabetes. While doctors have long suspected that poor sleep and liver health are connected, the precise nature of that relationship has remained murky. Specifically, it has been unclear whether the presence of diabetes makes sleep problems worse for people who already have fatty liver disease, or if the liver condition itself is the primary driver of sleep disruption regardless of blood sugar levels.
To untangle this complex web, researchers in Ahvaz, Iran, conducted a study involving 230 adults who were visiting a hospital for liver assessments. The team divided these participants into two main groups: those with type 2 diabetes and those without. They also categorized them based on whether they had MASLD, determined by a specialized ultrasound test that measures the amount of fat in the liver. The researchers did not rely on guesswork; they used four different, well-established questionnaires to get a detailed picture of each person's sleep. These tools measured everything from the severity of insomnia and the risk of obstructive sleep apnea—a condition where breathing stops repeatedly during sleep—to how tired people felt during the day and the overall quality of their rest. By comparing the answers from diabetic and non-diabetic individuals, and then looking at those with and without fatty liver, the team sought to see which factor played a bigger role in sleep disturbances.
The results revealed a clear distinction between the two conditions. People with diabetes were significantly more likely to suffer from obstructive sleep apnea than those without the disease. In fact, about 72.5 percent of the diabetic participants showed signs of this breathing disorder, compared to 57 percent of the non-diabetic group. However, when it came to other sleep issues, diabetes did not make things worse for those who already had fatty liver disease. The study found that having both diabetes and MASLD did not lead to more severe sleep problems than having MASLD alone. Instead, the presence of fatty liver disease itself was the stronger predictor for two specific issues: clinical insomnia and excessive daytime sleepiness. Individuals with MASLD were more likely to report trouble falling or staying asleep and feeling unusually tired during the day, regardless of whether they also had diabetes.
Perhaps the most intriguing finding concerned the relationship between the amount of fat in the liver and the severity of sleep problems. The researchers measured liver fat using a score called the controlled attenuation parameter, which provides a numerical value for how much fat is present. They discovered that in people without diabetes, higher levels of liver fat were directly linked to worse insomnia scores and a higher risk of sleep apnea. This suggests that in the absence of diabetes, the accumulation of fat in the liver may be a direct contributor to sleep disruption. However, this link disappeared in the group of people who had diabetes. For them, the amount of fat in the liver did not correlate with how poorly they slept. This implies that once diabetes is present, the metabolic chaos it creates may overshadow the specific impact of liver fat on sleep, making the liver fat level less relevant to the sleep issues a person experiences.
The study also highlighted that while the overall severity of sleep problems did not differ drastically between diabetic and non-diabetic groups, the specific types of disorders varied. The presence of diabetes seemed to tip the scales toward breathing-related sleep issues, while the liver condition tipped the scales toward trouble staying asleep and daytime fatigue. The researchers noted that their study had limitations, such as relying on self-reported questionnaires rather than overnight sleep monitoring in a lab, and that the cross-sectional nature of the work means they cannot prove that one condition causes the other. Nevertheless, the findings offer a clearer map of the landscape. They suggest that for patients with metabolic disorders, screening for sleep issues should be a routine part of care, but the specific type of sleep disorder to look for might depend on whether the patient has diabetes, fatty liver disease, or both. The presence of fatty liver disease appears to be a significant, independent factor in sleep health, urging doctors to consider the liver when a patient complains of poor rest, even if their blood sugar is under control.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.